You make a good point, and raise a question in my mind. If UNXL Management are not rewarded w/additional options for their accomplishments, are they not likely to file for a Shelf Offering to pad corporate cash? I raise this issue because that's what happened with each of my Drug Stocks (AMLN, DNDN, ELN) once they secured FDA approval and experienced the first "pop." If so, I'm hopeful that occurs north of $20/sh. Disclosure: Long $6+K shares at roughly $8/sh.